**About PharmaCare**

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

**Details of Drug Reviewed**

<table>
<thead>
<tr>
<th>Drug</th>
<th>glecaprevir-pibrentasvir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Maviret™</td>
</tr>
<tr>
<td>Dosage Form(s)</td>
<td>100 mg/40 mg tablet</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>AbbVie Corporation</td>
</tr>
<tr>
<td>Submission Type</td>
<td>New Submission</td>
</tr>
</tbody>
</table>

Use Reviewed

For the treatment of chronic hepatitis C (CHC)

Common Drug Review (CDR)

Yes, CDR recommended: **to Reimburse with clinical criteria and/or conditions**. Visit the CDR website for more details: [https://www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf](https://www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf)

Provincial Review

The DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry’s drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened Maviret™ on November 6, 2017. The DBC advised that because glecaprevir-pibrentasvir is similar to some of the other drugs used for the treatment of CHC, the Ministry may accept the CDEC recommendation for glecaprevir-pibrentasvir.

**Drug Coverage Decision**

Limited Coverage Benefit. Access the glecaprevir-pibrentasvir criteria from [www.gov.bc.ca/pharmacarespecialauthority](http://www.gov.bc.ca/pharmacarespecialauthority)

Date

March 21, 2019 (This supersedes the listing decision for the drug and indications dated January 29, 2019)

Reason(s)

**Drug coverage decision is consistent with CDEC recommendation.**

- Maviret™ reported high cure rates (based upon sustained viral response), is generally well-tolerated, and offers a shorter 8 weeks duration of therapy for treatment-naïve HCV patients without cirrhosis.
- Based on economic considerations and the submitted product price, Maviret™ was not cost effective and/or did not offer optimal value for money.
- The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer, which were able to address the concerns identified by CDEC with respect to cost-effectiveness and value for money.
- Effective **March 21, 2019**, PharmaCare is expanding the Maviret™ criteria for the treatment of adult patients with CHC genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including adult patients with CHC genotype 1 infection who were previously treated with direct-acting antivirals (DAA).

Other Information

None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- whether the drug is safe and effective
- advice from a national group called the Common Drug Review (CDR)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:
- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the The Drug Review Process in B.C. - Overview and Ministry of Health - PharmaCare for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.